Skip to main content

Advertisement

SpringerLink
Log in

Phosphaturic mesenchymal tumor: management and outcomes of ten patients treated at a single institution

  • Scientific Article
  • Published:
Skeletal Radiology Aims and scope Submit manuscript

Abstract

Background

Phosphaturic mesenchymal tumor (PMT) is a rare tumor that causes tumor-induced osteomalacia. Patients present with non-specific symptoms secondary to renal phosphate wasting and decreased bone mineralization. We sought to assess: (1) What are the common presenting features, laboratory and imaging findings, histologic findings of phosphaturic mesenchymal tumors? (2) What are the available treatment strategies for phosphaturic mesenchymal tumors and their long-term outcomes in terms of local recurrence and symptom control after treatment?

Methods

We retrospectively identified patients with a histologic diagnosis of PMT located in the axial or appendicular skeleton, or surrounding soft tissues. A total of 10 patients were finally included in our study.

Results

Median tumor size was 1.9 cm (range, 1.1 to 6.1) and median time from symptom onset to diagnosis was 3 years (range, 0.5 to 15 years). All patients but one presented with hypophosphatemia (median 1.9 mg/dL, range 1.2 to 3.2). Pre-operative FGF-23 was elevated in all cases (median 423.5 RU/mL, range 235 to 8950). Six patients underwent surgical resection, three were treated percutaneously (radiofrequency ablation or cryoablation), and one refused treatment. Only one patient developed local recurrence and no patients developed metastatic disease. At last follow-up, nine patients showed no evidence of disease and one was alive with disease.

Conclusion

Phosphaturic mesenchymal tumor is a rare tumor presenting with non-specific symptoms. Surgery is the standard treatment when negative margins can be achieved without significant morbidity. In patients with small tumors in surgically-inaccessible areas, radiofrequency ablation or cryoablation can be performed successfully.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

Study data available upon request and signed data agreement between institutions.

References

  1. Ledford CK, Zelenski NA, Cardona DM, Brigman BE, Eward WC. The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed? Clin Orthop Relat Res [Internet]. 2013;471:3618–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23868423.

  2. Schapira D, Ben Izhak O, Nachtigal A, Burstein A, Shalom RB, Shagrawi I, et al. Tumor-induced osteomalacia. Semin Arthritis Rheum [Internet]. 1995;25:35–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8525389.

  3. Horng JC, Van Eperen E, Tutton S, Singh R, Shaker JL, Wooldridge AN. Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation. Osteoporos Int. 2021;32:1895–8.

    Article  CAS  PubMed  Google Scholar 

  4. Pannu CD, Baxter D, Anwar H. Spinal phosphaturic mesenchymal tumors: a rare etiology causing tumor-induced osteomalacia-a review of experience at a UK tertiary referral center and literature review. Eur Spine J [Internet]. 2023. https://doi.org/10.1007/s00586-023-08031-6.

  5. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol [Internet]. 2004;28:1–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14707860.

  6. McCance RA. Osteomalacia with looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med [Internet]. 1947;16:33–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20296654.

  7. Prader A, Illig R, Uehlinger E, Stalder G. [Rickets following bone tumor]. Helv Paediatr Acta [Internet]. 1959;14:554–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14434619.

  8. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;18:53–77.

    Article  Google Scholar 

  9. Agus ZS. Oncogenic hypophosphatemic osteomalacia. Kidney Int [Internet]. 1983;24:113–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6312153.

  10. Mori Y, Ogasawara T, Motoi T, Shimizu Y, Chikazu D, Tamura K, et al. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature. Oral Surgery Oral Med Oral Pathol Oral Radiol Endodontology [Internet]. 2010;109:e57-63. https://doi.org/10.1016/j.tripleo.2009.10.052.

    Article  Google Scholar 

  11. Ogose A, Hotta T, Emura I, Hatano H, Inoue Y, Umezu H, et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol [Internet]. 2001;30:99–103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11310207.

  12. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer [Internet]. 1987;59:1442–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3545439.

  13. Malagon-Rangel J, Solis JG, Zavala-Jonguitud LF, Basile-Alvarez MR, Malagon-Liceaga A. Transformation of a long-standing phosphaturic tumor-inducing osteomalacia into malignancy. Clin Case Rep [Internet]. 2023;11:e8283. Available from: http://www.ncbi.nlm.nih.gov/pubmed/38076012.

  14. Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J [Internet]. 2015;62:811–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26135520.

  15. Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella SH, et al. Tumour-induced osteomalacia. Nat Rev Dis Prim [Internet]. 2017;3:1–15. https://doi.org/10.1038/nrdp.2017.44.

    Article  Google Scholar 

  16. Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone [Internet]. 2014;64:222–7. https://doi.org/10.1016/j.bone.2014.04.016.

    Article  CAS  PubMed  Google Scholar 

  17. Hofman MS, Lau WFE, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics [Internet]. 2015;35:500–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25763733.

  18. Clifton-Bligh RJ, Hofman MS, Duncan E, Sim I-W, Darnell D, Clarkson A, et al. Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab [Internet]. 2013;98:687–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23295468.

  19. Hussein MAM, Cafarelli FP, Paparella MT, Rennie WJ, Guglielmi G. Phosphaturic mesenchymal tumors: radiological aspects and suggested imaging pathway. Radiol Medica [Internet]. 2021;126:1609–18. https://doi.org/10.1007/s11547-021-01412-1.

    Article  Google Scholar 

  20. Benson JC, Trejo-Lopez JA, Nassiri AM, Eschbacher K, Link MJ, Driscoll CL, et al. Phosphaturic mesenchymal tumor. AJNR Am J Neuroradiol [Internet]. 2022;43:817–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35589138.

  21. Gupta A, Kandasamy D, Sharma R, Damle N, Goyal A, Goyal A, et al. Imaging characteristics of phosphaturic mesenchymal tumors. Acta Radiol. 2023;64:2061–73.

    Article  PubMed  Google Scholar 

  22. Broski SM, Folpe AL, Wenger DE. Imaging features of phosphaturic mesenchymal tumors. Skeletal Radiol. 2019;48:119–27.

    Article  PubMed  Google Scholar 

  23. Mishra SK, Kuchay MS, Sen IB, Garg A, Baijal SS, Mithal A. Successful management of tumor-induced osteomalacia with radiofrequency ablation: a case series. JBMR Plus. 2019;3:1–5.

    Article  Google Scholar 

  24. Tella SH, Amalou H, Wood BJ, Chang R, Chen CC, Robinson C, et al. Multimodality image-guided cryoablation for inoperable tumor-induced osteomalacia. J Bone Miner Res. 2017;32:2248–56.

    Article  CAS  PubMed  Google Scholar 

  25. Hesse E, Rosenthal H, Bastian L. Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med. 2007;357:422–4.

    Article  CAS  PubMed  Google Scholar 

  26. Jadhav S, Kasaliwal R, Shetty NS, Kulkarni S, Rathod K, Popat B, et al. Radiofrequency ablation, an effective modality of treatment in tumor-induced osteomalacia: a case series of three patients. J Clin Endocrinol Metab. 2014;99:3049–54.

    Article  CAS  PubMed  Google Scholar 

  27. Rosenthal D, Callstrom MR. Critical review and state of the art in interventional oncology: benign and metastatic disease involving bone. Radiology. 2012;262:765–80.

    Article  PubMed  Google Scholar 

  28. Econs MJ, Selen DJ, Balza R, Zurkiya O, Kronenberg HM, Hung YP. Case 18–2022: A 29-year-old woman with recurrent fractures. N Engl J Med [Internet]. 2022;386:2316–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35704485.

Download references

Author information

Authors and Affiliations

  1. Division of Orthopaedic Oncology, Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02144, USA

    Marcos R. Gonzalez, Neel Patel, Joseph J. Connolly & Santiago A. Lozano-Calderon

  2. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02144, USA

    Yin P. Hung

  3. Division of Musculoskeletal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02144, USA

    Connie Y. Chang

Authors
  1. Marcos R. Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neel Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph J. Connolly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yin P. Hung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Connie Y. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Santiago A. Lozano-Calderon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Santiago A. Lozano-Calderon.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Approval from the Institutional Review Board was obtained, and HIPAA requirements were followed. Informed consent was not required.

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gonzalez, M.R., Patel, N., Connolly, J.J. et al. Phosphaturic mesenchymal tumor: management and outcomes of ten patients treated at a single institution. Skeletal Radiol (2024). https://doi.org/10.1007/s00256-024-04614-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00256-024-04614-6

Keywords

Search

Navigation